Page 73 - Read Online

Page 12 of 12 Sabe et al. Vessel Plus 2024;8:2 https://dx.doi.org/10.20517/2574-1209.2023.95

american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2022;145:e895-
1032. DOI
18. Potz BA, Scrimgeour LA, Pavlov VI, Sodha NR, Abid MR, Sellke FW. Extracellular vesicle injection improves myocardial function
and increases angiogenesis in a swine model of chronic ischemia. J Am Heart Assoc 2018;7:e008344. DOI PubMed PMC
19. Scrimgeour LA, Potz BA, Aboul Gheit A, et al. Extracellular vesicles promote arteriogenesis in chronically ischemic myocardium in
the setting of metabolic syndrome. J Am Heart Assoc 2019;8:e012617. DOI PubMed PMC
20. Aboulgheit A, Karbasiafshar C, Zhang Z, et al. Lactobacillus plantarum probiotic induces Nrf2-mediated antioxidant signaling and
eNOS expression resulting in improvement of myocardial diastolic function. Am J Physiol Heart Circ Physiol 2021;321:H839-49.
DOI PubMed PMC
21. Elmadhun NY, Lassaletta AD, Chu LM, Liu Y, Feng J, Sellke FW. Atorvastatin increases oxidative stress and modulates
angiogenesis in Ossabaw swine with the metabolic syndrome. J Thorac Cardiovasc Surg 2012;144:1486-93. DOI PubMed PMC
22. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep
2017;7:16878. DOI PubMed PMC
23. Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial
infarction undergoing PCI: the SGLT2-I AMI PROTECT registry. Pharmacol Res 2023;187:106597. DOI PubMed PMC
24. Forzano I, Wilson S, Lombardi A, et al. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin
Investig Drugs 2023;32:839-47. DOI PubMed PMC
25. Wu YJ, Wang SB, Wang LS. SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction? Am J Cardiovasc Drugs
2022;22:601-13. DOI PubMed
26. Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and
glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med 2022;175:1392-400. DOI PubMed PMC
27. Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes
among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 2022;21:47. DOI PubMed PMC
28. Spoladore R, Pinto G, Daus F, Pezzini S, Kolios D, Fragasso G. Metabolic approaches for the treatment of dilated cardiomyopathy. J
Cardiovasc Dev Dis 2023;10:287. DOI PubMed PMC
29. Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH. Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4
inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. J Obes Metab Syndr
2019;28:254-61. DOI PubMed PMC
30. Banerjee D, Sabe SA, Xing H, et al. Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to
the myocardium independent of angiogenesis. J Thorac Cardiovasc Surg 2023;166:e535-50. DOI
31. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res 2012;111:800-14. DOI
PubMed PMC
32. Li X, Liu J, Lu Q, et al. AMPK: a therapeutic target of heart failure-not only metabolism regulation. Biosci Rep
2019;39:BSR20181767. DOI PubMed PMC
33. Harris DD, Sabe SA, Xu CM, et al. Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and
inflammation in a swine model for chronic myocardial ischemia. Surgery 2024;175:265-70. DOI
34. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and
clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008;8:754-67. DOI PubMed
35. Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces
mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension 2022;79:1633-43. DOI PubMed
PMC
36. Santulli G, Varzideh F, Forzano I, et al. Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart.
Hypertension 2023;80:1800-9. DOI PubMed PMC